Is imjudo, the new drug for hepatocellular carcinoma, tremelimumab? What medicine is it?

Tremelimumab/tremelimumab was initially obtained in October 2022 in the United States in October 2022 by the U.S. Food and Drug Administration (FDA), and Sold under the brand name imjudo, it contains tremelimumab, a human monoclonal antibody directed against the activity of cytotoxic T lymphocyte-associated protein 4 (CTLA-4), which is expressed on the surface of T lymphocytes. By blocking the activity of CTLA-4, tremelimumab helps T cells activate, trigger an immune response to cancer, and promote cancer cell death.

Tremelimumab, a cytotoxicT lymphocyte-associated antigen 4 (CTLA-4) blocking antibody, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) in combination with durvalumab , and in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of tremelimumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL), which is still relatively expensive. At present, we are not aware of any generic version of Tremelimumab that has been produced and launched on the market. For specific overseas prices and drug details, please consult Yade Medical Consultants.